Navigation Links
Researchers discover protein that controls bone growth
Date:12/19/2007

A research team led by Dr. Pierre Moffatt of the Shriners Hospital for Children in Montreal and McGill Universitys Department of Human Genetics has uncovered the molecular mechanism by which the protein osteocrin controls bone growth a discovery that may have important implications for people suffering from bone diseases affecting skeletal growth. The teams findings appear in the December 14 edition of the Journal of Biological Chemistry.

Osteocrin is a small protein produced by the bodys bone-forming cells, or osteoblasts. In this study, mice that were genetically engineered to over-express osteocrin developed hunchbacks and elongated bones. This led Dr. Moffatt and his colleagues to the discovery that osteocrin locally controls the bone's supply of a hormone known as CNP, which plays an important role in the regulation of bone growth.

The osteocrin gene was discovered as part of a project to identify novel bone genes that might have possible therapeutic actions, explained Dr. Moffatt. "The project focused on the identification of classes of genes which are particularly attractive to medical researchers because they can be potentially exploited to develop new drug-based therapies."

Most of the research was initially carried out at Phenogene and Enobia Pharma, two Montreal-based biotech companies, but it was finalized in Dr. Moffatts lab at the Shriners Hospital for Children in Montreal.

This fundamental research could pave the way to the rationalized design of new molecules which could have beneficial effects in various disorders that impair bone growth, particularly in children, said Dr. Moffatt.


'/>"/>

Contact: Mark Shainblum
mark.shainblum@mcgill.ca
514-398-2189
McGill University
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Opal Kelly, a leading producer ... using USB or PCI Express, announced the FOMD-ACV-A4, the company's first FPGA-on-Module for ... thin, SODIMM-style module that fits a standard 204-pin SODIMM socket for low-cost integrations ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc announced today ... demand KbioBox developed a sophisticated “3 click” gene dditing off target analysis program ... new website, https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
(Date:12/8/2016)... 8, 2016 Eutilex Co. Ltd. today announced ... $18.9M) Series A financing. This financing round included participation ... and SNU Bio Angel. This new funding brings the ... (US $27.7M) since its founding in 2015. ... development and commercialization of its immuno-oncology programs, expand its ...
Breaking Biology Technology: